Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Defining EGFR amplification status for clinical trial inclusion.

French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M.

Neuro Oncol. 2019 May 24. pii: noz096. doi: 10.1093/neuonc/noz096. [Epub ahead of print]

PMID:
31125418
2.

Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies.

Zheng PP, Kros JM, Wang G.

Trends Immunol. 2019 Apr;40(4):274-278. doi: 10.1016/j.it.2019.02.005. Epub 2019 Mar 12.

PMID:
30876815
3.

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.

Synhaeve NE, van den Bent MJ, French PJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Verdijk R, Dirven CMF, Dubbink HJ.

Acta Neuropathol Commun. 2018 Nov 23;6(1):126. doi: 10.1186/s40478-018-0633-y.

4.

Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors.

Zhu C, Mustafa DAM, Krebber MM, Chrifi I, Leenen PJM, Duncker DJ, Dekker L, Luider TM, Kros JM, Cheng C.

Oncotarget. 2018 Sep 11;9(71):33500-33514. doi: 10.18632/oncotarget.26063. eCollection 2018 Sep 11.

5.

The complement system in glioblastoma multiforme.

Bouwens van der Vlis TAM, Kros JM, Mustafa DAM, van Wijck RTA, Ackermans L, van Hagen PM, van der Spek PJ.

Acta Neuropathol Commun. 2018 Sep 12;6(1):91. doi: 10.1186/s40478-018-0591-4. Review.

6.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
7.

CMTM4 regulates angiogenesis by promoting cell surface recycling of VE-cadherin to endothelial adherens junctions.

Chrifi I, Louzao-Martinez L, Brandt MM, van Dijk CGM, Bürgisser PE, Zhu C, Kros JM, Verhaar MC, Duncker DJ, Cheng C.

Angiogenesis. 2019 Feb;22(1):75-93. doi: 10.1007/s10456-018-9638-1. Epub 2018 Aug 10.

8.

Heterogeneity within the PF-EPN-B ependymoma subgroup.

Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V.

Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.

PMID:
30019219
9.

Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis.

Pedrosa RMSM, Mustafa DAM, Aerts JGJV, Kros JM.

Front Oncol. 2018 May 11;8:159. doi: 10.3389/fonc.2018.00159. eCollection 2018. Review.

10.

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies.

van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ.

Cytometry B Clin Cytom. 2018 Nov;94(6):928-934. doi: 10.1002/cyto.b.21641. Epub 2018 Sep 3.

PMID:
29747221
11.

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ.

J Neurooncol. 2018 Sep;139(2):349-357. doi: 10.1007/s11060-018-2867-8. Epub 2018 Apr 16.

12.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ.

Eur J Cancer. 2018 May;94:168-178. doi: 10.1016/j.ejca.2018.02.023. Epub 2018 Mar 20.

PMID:
29571083
13.

Breast cancer brain metastasis: molecular mechanisms and directions for treatment.

Pedrosa RMSM, Mustafa DA, Soffietti R, Kros JM.

Neuro Oncol. 2018 Oct 9;20(11):1439-1449. doi: 10.1093/neuonc/noy044.

PMID:
29566179
14.

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts.

Zheng PP, Kros JM, Li J.

Drug Discov Today. 2018 Jun;23(6):1175-1182. doi: 10.1016/j.drudis.2018.02.012. Epub 2018 Mar 1.

15.

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.

Mustafa DAM, Pedrosa RMSM, Smid M, van der Weiden M, de Weerd V, Nigg AL, Berrevoets C, Zeneyedpour L, Priego N, Valiente M, Luider TM, Debets R, Martens JWM, Foekens JA, Sieuwerts AM, Kros JM.

Acta Neuropathol. 2018 Apr;135(4):581-599. doi: 10.1007/s00401-018-1806-2. Epub 2018 Jan 19.

16.

Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification.

Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent AJPE, van den Bent MJ.

Acta Neuropathol. 2017 Dec;134(6):957-959. doi: 10.1007/s00401-017-1781-z. Epub 2017 Oct 19. No abstract available.

PMID:
29052002
17.

Cgnl1, an endothelial junction complex protein, regulates GTPase mediated angiogenesis.

Chrifi I, Hermkens D, Brandt MM, van Dijk CGM, Bürgisser PE, Haasdijk R, Pei J, van de Kamp EHM, Zhu C, Blonden L, Kros JM, Duncker DJ, Duckers HJ, Cheng C.

Cardiovasc Res. 2017 Dec 1;113(14):1776-1788. doi: 10.1093/cvr/cvx175.

18.

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ.

Neuro Oncol. 2018 Jan 10;20(1):103-112. doi: 10.1093/neuonc/nox176.

19.

Improving the characterization of endothelial progenitor cell subsets by an optimized FACS protocol.

Huizer K, Mustafa DAM, Spelt JC, Kros JM, Sacchetti A.

PLoS One. 2017 Sep 14;12(9):e0184895. doi: 10.1371/journal.pone.0184895. eCollection 2017.

20.

Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes.

van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, Will LM, Hulsenboom E, Demonet JF, Sabater L, Kros JM, Verschuuren JJGM, Titulaer MJ, de Graaff E, Sillevis Smitt PAE, Hoogenraad CC.

Ann Clin Transl Neurol. 2017 Jul 28;4(9):680-686. doi: 10.1002/acn3.396. eCollection 2017 Sep.

21.

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Zheng PP, Li J, Kros JM.

Med Res Rev. 2018 Jan;38(1):325-376. doi: 10.1002/med.21463. Epub 2017 Sep 1. Review.

22.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

23.

Mutations targeting the coagulation pathway are enriched in brain metastases.

Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, Pruneri G, Sciandivasci A, Munzone E, DiMeco F, Pelicci PG, Riva L, Pelicci G.

Sci Rep. 2017 Jul 26;7(1):6573. doi: 10.1038/s41598-017-06811-x.

24.

Diffuse Infiltrating Oligodendroglioma and Astrocytoma.

van den Bent MJ, Smits M, Kros JM, Chang SM.

J Clin Oncol. 2017 Jul 20;35(21):2394-2401. doi: 10.1200/JCO.2017.72.6737. Epub 2017 Jun 22. Review.

PMID:
28640702
25.

Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD.

Cancer Cell. 2017 Jun 12;31(6):737-754.e6. doi: 10.1016/j.ccell.2017.05.005.

26.

The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.

Zhu C, Kros JM, Cheng C, Mustafa D.

Neuro Oncol. 2017 Oct 19;19(11):1435-1446. doi: 10.1093/neuonc/nox081. Review.

27.

CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma.

Zhu C, Chrifi I, Mustafa D, van der Weiden M, Leenen PJM, Duncker DJ, Kros JM, Cheng C.

Oncogene. 2017 Sep 21;36(38):5356-5368. doi: 10.1038/onc.2017.145. Epub 2017 May 22.

28.

Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.

Zhu C, Mustafa D, Zheng PP, van der Weiden M, Sacchetti A, Brandt M, Chrifi I, Tempel D, Leenen PJM, Duncker DJ, Cheng C, Kros JM.

Neuro Oncol. 2017 May 1;19(5):648-659. doi: 10.1093/neuonc/now251.

29.

CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions.

Chrifi I, Louzao-Martinez L, Brandt M, van Dijk CGM, Burgisser P, Zhu C, Kros JM, Duncker DJ, Cheng C.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1098-1114. doi: 10.1161/ATVBAHA.116.308792. Epub 2017 Apr 20.

PMID:
28428220
30.

Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Rudà R, Tonn JC, Weber DC, Weller M.

Neuro Oncol. 2017 Feb 1;19(2):162-174. doi: 10.1093/neuonc/now241.

31.

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S.

Neuro Oncol. 2017 May 1;19(5):614-624. doi: 10.1093/neuonc/now277. Review.

32.

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, Neggers SJCMM, van der Lely AJ, Lamberts SWJ, Ferone D, Hofland LJ.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):2009-2018. doi: 10.1210/jc.2017-00135.

PMID:
28323931
33.

A rare missense variant in RCL1 segregates with depression in extended families.

Amin N, de Vrij FMS, Baghdadi M, Brouwer RWW, van Rooij JGJ, Jovanova O, Uitterlinden AG, Hofman A, Janssen HLA, Darwish Murad S, Kraaij R, Stedehouder J, van den Hout MCGN, Kros JM, van IJcken WFJ, Tiemeier H, Kushner SA, van Duijn CM.

Mol Psychiatry. 2018 May;23(5):1120-1126. doi: 10.1038/mp.2017.49. Epub 2017 Mar 21.

34.

Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade.

Zhu C, Kros JM, van der Weiden M, Zheng P, Cheng C, Mustafa DA.

Acta Neuropathol Commun. 2017 Jan 10;5(1):4. doi: 10.1186/s40478-016-0405-5.

35.

Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland.

Pivonello R, Waaijers M, Kros JM, Pivonello C, de Angelis C, Cozzolino A, Colao A, Lamberts SWJ, Hofland LJ.

Endocrine. 2017 Aug;57(2):314-325. doi: 10.1007/s12020-016-1107-2. Epub 2016 Oct 13.

PMID:
27738887
36.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

37.

Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.

Dubbink HJ, Atmodimedjo PN, van Marion R, Krol NMG, Riegman PHJ, Kros JM, van den Bent MJ, Dinjens WNM.

J Mol Diagn. 2016 Sep;18(5):775-786. doi: 10.1016/j.jmoldx.2016.06.002. Epub 2016 Jul 25. Erratum in: J Mol Diagn. 2016 Nov;18(6):933.

PMID:
27461031
38.

Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome.

Meuwissen ME, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD, Li Z, van Unen L, Heijsman D, Goldmann T, Lequin MH, Kros JM, Stam W, Hermann M, Willemsen R, Brouwer RW, Van IJcken WF, Martin-Fernandez M, de Coo I, Dudink J, de Vries FA, Bertoli Avella A, Prinz M, Crow YJ, Verheijen FW, Pellegrini S, Bogunovic D, Mancini GM.

J Exp Med. 2016 Jun 27;213(7):1163-74. doi: 10.1084/jem.20151529. Epub 2016 Jun 20.

39.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD.

Lancet Oncol. 2016 Apr;17(4):484-495. doi: 10.1016/S1470-2045(15)00581-1. Epub 2016 Mar 12.

40.

Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.

Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, van der Lely AJ, Neggers SJ, Lamberts SW, Pereira AM, Ferone D, Hofland LJ.

Eur J Endocrinol. 2016 May;174(5):651-62. doi: 10.1530/EJE-15-0391. Epub 2016 Feb 17.

PMID:
26888629
41.

Myocarditis in patients with subarachnoid hemorrhage: A histopathologic study.

van der Bilt IA, Vendeville JP, van de Hoef TP, Begieneman MP, Lagrand WK, Kros JM, Wilde AA, Rinkel GJ, Niessen HW.

J Crit Care. 2016 Apr;32:196-200. doi: 10.1016/j.jcrc.2015.12.005. Epub 2015 Dec 11.

PMID:
26777746
42.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.

Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.

43.

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.

Mustafa DA, Sieuwerts AM, Smid M, de Weerd V, van der Weiden M, Meijer-van Gelder ME, Martens JW, Foekens JA, Kros JM.

PLoS One. 2015 Dec 30;10(12):e0144097. doi: 10.1371/journal.pone.0144097. eCollection 2015.

44.

Catecholamine-induced cardiomyopathy in a patient with malignant paraganglioma.

Heijneman JA, Boere IA, Feelders RA, de Herder WW, Kros JM, Manintveld OC, Verduijn GM.

Neth J Med. 2015 Dec;73(10):483-6. No abstract available.

45.

KINFix--A formalin-free non-commercial fixative optimized for histological, immunohistochemical and molecular analyses of neurosurgical tissue specimens.

Stefanits H, Bienkowski M, Galanski M, Mitulovic G, Ströbel T, Gelpi E, Ribalta T, Broholm H, Hartmann C, Kros JM, Preusser M, Hainfellner JA.

Clin Neuropathol. 2016 Jan-Feb;35(1):3-12. doi: 10.5414/NP300907.

46.

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.

De Meyer T, Bady P, Trooskens G, Kurscheid S, Bloch J, Kros JM, Hainfellner JA, Stupp R, Delorenzi M, Hegi ME, Van Criekinge W.

Sci Rep. 2015 Oct 20;5:15375. doi: 10.1038/srep15375.

47.

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, Wesseling P, Enting R, Spliet W, Tijssen C, Dinjens WN, Gorlia T, van den Bent MJ.

Neuro Oncol. 2016 Mar;18(3):388-400. doi: 10.1093/neuonc/nov182. Epub 2015 Sep 9.

48.

Contemporary frameless intracranial biopsy techniques: Might variation in safety and efficacy be expected?

Verploegh IS, Volovici V, Haitsma IK, Schouten JW, Dirven CM, Kros JM, Dammers R.

Acta Neurochir (Wien). 2015 Nov;157(11):2011-6; discussion 2016. doi: 10.1007/s00701-015-2543-0. Epub 2015 Aug 29.

49.

Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials.

Kros JM, Huizer K, Hernández-Laín A, Marucci G, Michotte A, Pollo B, Rushing EJ, Ribalta T, French P, Jaminé D, Bekka N, Lacombe D, van den Bent MJ, Gorlia T.

J Clin Oncol. 2015 Jun 10;33(17):1943-50. doi: 10.1200/JCO.2014.59.0166. Epub 2015 Apr 27.

PMID:
25918297
50.

Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation.

Erdem-Eraslan L, Gao Y, Kloosterhof NK, Atlasi Y, Demmers J, Sacchetti A, Kros JM, Sillevis Smitt P, Aerts J, French PJ.

Eur J Cancer. 2015 May;51(7):893-903. doi: 10.1016/j.ejca.2015.02.006. Epub 2015 Mar 5.

Supplemental Content

Support Center